Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Venture Prepares for Structured Acquisitions

This article was originally published in Start Up

Executive Summary

With Big Pharma content to sit on the sidelines and wait as biotech company valuations continue their fall, the M&A activity that does take place is likely to place a premium on hedging risk. And, say venture investors, that means structured acquisitions of biotech firms are likely to increase as pharmaceutical acquirers gain more leverage over cash-strapped firms in deal negotiations.

You may also be interested in...



H.I.G. BioVentures Closes Second Fund Above Target, Team Upbeat

H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.

Best of the Blog: IN VIVO February 2009

A roundup of our best February blog posts not covered elsewhere in the magazine includes Biotech's Winter and the March of the EarnOuts; Infant formula division Mead Johnson milks investors of $720 million in IPO; Dont Come Knockin' on my Door: Survey shows physicians restrict drug rep access.

Best of the Blog: IN VIVO February 2009

A roundup of our best February blog posts not covered elsewhere in the magazine includes Biotech's Winter and the March of the EarnOuts; Infant formula division Mead Johnson milks investors of $720 million in IPO; Dont Come Knockin' on my Door: Survey shows physicians restrict drug rep access.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel